Tapping Chinese investors, Apexigen closes $73M for 8 trials in I/O
Apexigen, a small company in California, just closed a couple rounds of cash totaling $73 million — mostly from Chinese investors — to push forward a slew of immuno-oncology programs.
The company is using the capital to advance its lead product candidate called APX005M, a monoclonal antibody targeting CD40. Apexigen is already in several Phase II studies on the drug, testing different types of cancer including melanoma, non-small cell lung cancer, pancreatic cancer and renal cell carcinoma in various combos with immunotherapy, chemotherapy or radiation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.